mp2

XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograft model.

MP265 disrupts the MreB cytoskeleton and has antiproliferative effects.

Myelopeptide-2 (MP-2) with the sequence Leu-Val-Val-Tyr-Pro-Trp is originally isolated from the supernatant of porcine bone marrow cell culture and is able to restore the mitogen responsiveness of human T lymphocytes inhibited by conditioned medium from H

BMP2-derived peptide, encompassing amino acids 73 to 92 of BMP-2, induces osteogenic differentiation in bone marrow stromal cells (BMSCs) and augments bone regeneration [1].

IMP2-IN-2 is a potent and selective inhibitor of IMP2 with IC50 values of 120.9 μM and 236.7 μM for the inhibition of IMP2 interaction with RNA_A and RNA_B, respectively. IMP2-IN-2 can be used in cancer research.

AIMP2-DX2-IN-1 is a potent AIMP2-DX2 inhibitor with potential antitumor activity for the study of lymphoma.

TMP269 is an effective, specific class IIa HDAC inhibitor for HDAC4 (IC50: 157 nM), HDAC5 (IC50: 97 nM), HDAC7 (IC50: 43 nM), and HDAC9 (IC50: 23 nM), respectively.

MMP2-IN-2 is a selective MMP-2 (matrix metalloproteinase) inhibitor with potential anticancer and antitumor activity, inhibits MMP-13, MMP-9, and MMP-8, and can be used in the study of cancer and immune disorders.

MMP2-IN-3 is a potent inhibitor of matrix metalloproteinases (MMP-2) (IC50: 31 μM). MMP2-IN-3 inhibits MMP-9 and MMP-8 with IC50s of 26.6 and 32 μM, respectively.

MMP2-IN-1 shows siganificant antiproliferative activity in certain cancer cells through arresting the cell cycle and inducing apoptosis. MMP2-IN-1 is a moderate potenet inhibitor of MMP2 (IC 50 = 6.8 μM)[1].

IMP2-IN-1 (compound 4) is an effective IMP2 inhibitor with an IC50 of 81.3-127.5 μM for IMP2 RNA . IMP2-IN-1 decreased the level of IMP2 in SW480 cells. IMP2-IN-1 significantly inhibited the activity of differentiated and undifferentiated Huh7 cells.

Risvodetinib, a potent inhibitor of protein tyrosine kinases, specifically targets the synthesis of Abelson protein kinases (c-Abl1, c-Abl2, and c-kit).